Investiation of rivaroxaban as a safe and effective alternative to warfarin for venous thromboembolism (VTE) treatment and prevention of stroke in patients with atrial fibrillation
Latest Information Update: 10 Nov 2019
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Therapeutic Use
Most Recent Events
- 09 Nov 2019 New trial record
- 31 Oct 2019 Primary endpoint (incidence of clinical failure, defined as VTE recurrence, stroke incidence, and mortality, within 12 months of initiation.) has not been met according to results published in Annals of Pharmacotherapy.
- 31 Oct 2019 Results published in the Annals of Pharmacotherapy